Neos Therapeutics, Inc.
Neos Therapeutics, Inc. (NEOS): 5 pipeline candidates · ~31 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
31.4 months
0% dilution
Lead: Approved
5 candidates
N/A
N/A
A transparent, data-derived signal for Neos Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$12.7M
Quarterly Burn
$2.1M
Runway
31.4 mo
Revenue
$12.5M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| adzenys er | Approved |
| adzenys xr-odt | Approved |
| cotempla xr-odt | Approved |
| nt-0400 | Preclinical |
| nt0502 | Preclinical |
Frequently asked questions
How many drug candidates are in Neos Therapeutics, Inc.'s pipeline?
Neos Therapeutics, Inc. (NEOS) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Neos Therapeutics, Inc.'s lead drug candidate?
Neos Therapeutics, Inc.'s most advanced tracked candidate is adzenys er (Approved) for Treatment of ADHD in patients 6 years and older.
What is Neos Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Neos Therapeutics, Inc. has approximately 31.4 months of cash runway.
Who is the CEO of Neos Therapeutics, Inc.?
Gerald Mc is the chief executive officer of Neos Therapeutics, Inc. (NEOS).
Get the full picture on Neos Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.